Piperlongumine (Synonyms: Piplartine; ピペルロングミン)

Name: Piperlongumine
Brand: MedChemExpress
SKU: HY-N2329
Rating: 5.0 (14 reviews)

製品番号: HY-N2329 純度: 99.86%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Piperlongumine is a alkaloid, possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines. Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway. Piperlongumin could be used in the study of migrasome.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 20069-09-4

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 33	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 33	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$30	在庫あり	Estimated Time of Arrival: December 31
10 mg	$40	在庫あり	Estimated Time of Arrival: December 31
25 mg	$64	在庫あり	Estimated Time of Arrival: December 31
50 mg	$100	在庫あり	Estimated Time of Arrival: December 31
100 mg	$150	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 14 publication(s) in Google Scholar

Other Forms of Piperlongumine:

Piperlongumine (Standard) お問い合わせ

顧客検証

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

Histological Imaging/Staining

RT-PCR

: Piperlongumine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Dec 23:e17792. [Abstract]; Dose‐response curves and IC₅₀ values of DOX and Piperlongumine (PL, 24 h) against HCCLM3 and Hepa1‐6 cells.

: Piperlongumine purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156606.; Piperlongumine (PL, 10 mg/kg; i.p.; once every two days for 7 days) significantly improved body weight and survival rate in mice following CVB3 infection.

: Piperlongumine purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156606.; Piperlongumine (PL, 10 mg/kg; i.p.; once every two days for 7 days) significantly alleviated CVB3-induced myocardial injury in mice.

: Piperlongumine purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156606.; Statistical analysis of TNF-α, IL-1β, IL-6, and MCP-1 mRNA expression levels in mouse hearts of each group using RT-qPCR (n = 3). The expression levels were expressed as ratio relative to GAPDH. The results showed that Piperlongumine (PL, 10 mg/kg; i.p.; once every two days for 7 days) significantly attenuated the CVB3-induced upregulation of IL-1β, IL-6, TNF-α and MCP-1 in mice.

: Piperlongumine purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156606.; HL-1 cells were treated with indicated doses of Piperlongumine (PL, 0.625-160 µM) for 24 h. The cell viability rate was calculated by CCK-8 assay. The results indicated that PL did not affect HL-1 cell proliferation at concentrations of 20 µM or less.

: Piperlongumine purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156606.; Total protein of treated HL-1 cells was analyzed by western blotting. The relative levels of pyroptosis related proteins were normalized to that of GAPDH (n = 3). The results demonstrated that Piperlongumine (PL, 10 µM; 24 h) attenuated CVB3-induced cardiomyocyte pyroptosis in vitro.

: Piperlongumine purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156606.; Piperlongumine (PL, 10 µM; 24 h) reversed the increased expression and aggregation of the N‑terminal fragment of gasdermin D (GSDMD‑N) induced by CVB3 in HL‑1 cells.

: Piperlongumine purchased from MedChemExpress. Usage Cited in: Transl Cancer Res. 2023 Oct 31;12(10):2911-2922.; Piperlongumine (PL) affectes the expression of ferroptosis related proteins in OSCC cells. PL (6, 12, 24 h) increases the expression of DMT1 in OSCC cells, and decreases the expression of FTH1, SLC7A11 and GPX4.

ERK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

ERK ERK1 ERK2 ERK5 ERK8

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Piperlongumine is a alkaloid^[1], possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities^[2]. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines^[1]. Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway. Piperlongumin could be used in the study of migrasome^[2]^[3].

IC₅₀ & Target^[2]

ERK1

ERK2

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	EC₅₀	6.17 3 Compound: piperlongumine	Antiproliferative activity against human A375 cells after 72 hrs by MTT assay Antiproliferative activity against human A375 cells after 72 hrs by MTT assay	[PMID: 25826398]
8-MG-BA	IC₅₀	10 3 Compound: PL	Antiproliferative activity against human 8-MG-BA cells assessed as cell growth inhibition Antiproliferative activity against human 8-MG-BA cells assessed as cell growth inhibition	[PMID: 33930801]
A549	ED₅₀	0.6 6 Compound: 3	Cytotoxicity against human A549 cells after 6 days by MTT assay Cytotoxicity against human A549 cells after 6 days by MTT assay	[PMID: 2089124]
A-375	EC₅₀	6.17 3 Compound: piperlongumine	Antiproliferative activity against human A375 cells after 72 hrs by MTT assay Antiproliferative activity against human A375 cells after 72 hrs by MTT assay	[PMID: 25826398]
A-375	EC₅₀	6.17 3 Compound: piperlongumine	Antiproliferative activity against human A375 cells after 72 hrs by MTT assay Antiproliferative activity against human A375 cells after 72 hrs by MTT assay	[PMID: 25826398]
A549	IC₅₀	1.76 3 Compound: Piperlongumine	Inhibition of NF-kappaB in human A549 cells after 24 hrs by luciferase reporter gene assay Inhibition of NF-kappaB in human A549 cells after 24 hrs by luciferase reporter gene assay	[PMID: 27810594]
A-375	IC₅₀	2.5 3 Compound: PL	Antiproliferative activity against human A-375 cells assessed as cell growth inhibition Antiproliferative activity against human A-375 cells assessed as cell growth inhibition	[PMID: 33930801]
A-375	IC₅₀	2.5 3 Compound: PL	Antiproliferative activity against human A-375 cells assessed as cell growth inhibition Antiproliferative activity against human A-375 cells assessed as cell growth inhibition	[PMID: 33930801]
A549	EC₅₀	12.2 3 Compound: piperlongumine	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 25826398]
A549	IC₅₀	10 3 Compound: 1; PL	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
A549	EC₅₀	12.2 3 Compound: piperlongumine	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 25826398]
A549	EC₅₀	12.2 3 Compound: piperlongumine	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 25826398]
A549	ED₅₀	0.6 6 Compound: 3	Cytotoxicity against human A549 cells after 6 days by MTT assay Cytotoxicity against human A549 cells after 6 days by MTT assay	[PMID: 2089124]
A549	ED₅₀	0.6 6 Compound: 3	Cytotoxicity against human A549 cells after 6 days by MTT assay Cytotoxicity against human A549 cells after 6 days by MTT assay	[PMID: 2089124]
A549	IC₅₀	1.76 3 Compound: Piperlongumine	Inhibition of NF-kappaB in human A549 cells after 24 hrs by luciferase reporter gene assay Inhibition of NF-kappaB in human A549 cells after 24 hrs by luciferase reporter gene assay	[PMID: 27810594]
A549	IC₅₀	15.28 3 Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29424539]
A549	IC₅₀	15.22 3 Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human A549 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
A549	IC₅₀	10 3 Compound: 1; PL	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
A549	IC₅₀	15.28 3 Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29424539]
A549	IC₅₀	6.84 3 Compound: PL	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28434764]
A549	IC₅₀	22.85 3 Compound: PL	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 24937186]
A549	IC₅₀	10.17 3 Compound: PL	Antiproliferative activity against human A549 cells assessed as cell growth inhibition Antiproliferative activity against human A549 cells assessed as cell growth inhibition	[PMID: 33930801]
A549	IC₅₀	3.2 3 Compound: 1; PL	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
A549	IC₅₀	13.2 3 Compound: 1	Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay	[PMID: 39045852]
A549	IC₅₀	15.22 3 Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human A549 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
A549	IC₅₀	3.2 3 Compound: 1; PL	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
A549	IC₅₀	6.54 3 Compound: PL	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
A549	IC₅₀	15.22 3 Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human A549 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
A549	IC₅₀	10.17 3 Compound: PL	Antiproliferative activity against human A549 cells assessed as cell growth inhibition Antiproliferative activity against human A549 cells assessed as cell growth inhibition	[PMID: 33930801]
A549	IC₅₀	6.84 3 Compound: PL	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28434764]
A549	IC₅₀	4.998 3 Compound: PL	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
A549	IC₅₀	15.28 3 Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29424539]
Bel-7402	IC₅₀	5.6 3 Compound: 1	Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
A549	IC₅₀	22.85 3 Compound: PL	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 24937186]
A549	IC₅₀	22.85 3 Compound: PL	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 24937186]
A549	IC₅₀	6.54 3 Compound: PL	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
A549	IC₅₀	3.2 3 Compound: 1; PL	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
Bel-7402	IC₅₀	5.6 3 Compound: PL	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
A549	IC₅₀	4.998 3 Compound: PL	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
Bel7402/5-FU	IC₅₀	8.4 3 Compound: 1	Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
A549	IC₅₀	10 3 Compound: 1; PL	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
A549	IC₅₀	6.54 3 Compound: PL	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
A549	IC₅₀	1.76 3 Compound: Piperlongumine	Inhibition of NF-kappaB in human A549 cells after 24 hrs by luciferase reporter gene assay Inhibition of NF-kappaB in human A549 cells after 24 hrs by luciferase reporter gene assay	[PMID: 27810594]
Bel7402/5-FU	IC₅₀	8.4 3 Compound: PL	Cytotoxicity against human BEL-7402/5-FU cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human BEL-7402/5-FU cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
BHK-21	CC₅₀	40.14 3 Compound: Piplartine	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31009908]
A549	IC₅₀	6.84 3 Compound: PL	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28434764]
CMK	IC₅₀	1911 1 Compound: PL	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
A549	IC₅₀	7.2 3 Compound: 1	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 39045852]
Bel-7402	IC₅₀	5.6 3 Compound: 1	Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
CMK	IC₅₀	2815 1 Compound: PL	Antiproliferative activity against human CMK cells after 72 hrs by MTT assay Antiproliferative activity against human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
Bel-7402	IC₅₀	5.6 3 Compound: PL	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
CMK	IC₅₀	421.8 1 Compound: PL	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
Bel7402/5-FU	IC₅₀	8.4 3 Compound: 1	Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
AGS	IC₅₀	20 3 Compound: PL	Antiproliferative activity against human AGS cells assessed as cell growth inhibition Antiproliferative activity against human AGS cells assessed as cell growth inhibition	[PMID: 33930801]
CMK	IC₅₀	612.7 1 Compound: PL	Antiproliferative activity against human CMK cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human CMK cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
BHK-21	CC₅₀	40.14 3 Compound: Piplartine	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31009908]
Bel7402/5-FU	IC₅₀	8.4 3 Compound: PL	Cytotoxicity against human BEL-7402/5-FU cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human BEL-7402/5-FU cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
DU-145	GI₅₀	7.1 3 Compound: 1; PL	Growth inhibition of human DU145 cells after 48 hrs by WST-1 assay Growth inhibition of human DU145 cells after 48 hrs by WST-1 assay	[PMID: 29807795]
Bel-7402	IC₅₀	5.6 3 Compound: 1	Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
BHK-21	CC₅₀	40.14 3 Compound: Piplartine	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31009908]
HaCaT	IC₅₀	16 3 Compound: PL, piplartine	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	[PMID: 25305718]
Bel-7402	IC₅₀	5.6 3 Compound: PL	Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
Bel7402/5-FU	IC₅₀	8.4 3 Compound: 1	Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
DU-145	GI₅₀	7.1 3 Compound: 1; PL	Growth inhibition of human DU145 cells after 48 hrs by WST-1 assay Growth inhibition of human DU145 cells after 48 hrs by WST-1 assay	[PMID: 29807795]
HaCaT	IC₅₀	3.03 3 Compound: 3	Cytotoxicity against human HaCaT assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
HaCaT	EC₅₀	4.46 3 Compound: piperlongumine	Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay	[PMID: 25826398]
Bel7402/5-FU	IC₅₀	8.4 3 Compound: PL	Cytotoxicity against human BEL-7402/5-FU cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human BEL-7402/5-FU cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
DU-145	IC₅₀	3.4 3 Compound: PL	Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition	[PMID: 33930801]
HCT-116	EC₅₀	11.5 3 Compound: piperlongumine	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25826398]
HaCaT	EC₅₀	4.46 3 Compound: piperlongumine	Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay	[PMID: 25826398]
CCRF-CEM	IC₅₀	4.4 3 Compound: PL	Antiproliferative activity against human CEM cells assessed as cell growth inhibition Antiproliferative activity against human CEM cells assessed as cell growth inhibition	[PMID: 33930801]
CMK	IC₅₀	1911 1 Compound: PL	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
HaCaT	IC₅₀	3.03 3 Compound: 3	Cytotoxicity against human HaCaT assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
HCT-116	IC₅₀	6.04 3 Compound: PL	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24937186]
HCT-116	IC₅₀	6.38 3 Compound: PL	Cytotoxicity against human HCT-116 incubated for 24 hrs by CCK-8 assay Cytotoxicity against human HCT-116 incubated for 24 hrs by CCK-8 assay	[PMID: 35696861]
HaCaT	IC₅₀	16 3 Compound: PL, piplartine	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	[PMID: 25305718]
CMK	IC₅₀	2815 1 Compound: PL	Antiproliferative activity against human CMK cells after 72 hrs by MTT assay Antiproliferative activity against human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
HCT-116	IC₅₀	6.9 3 Compound: PL	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
CMK	IC₅₀	421.8 1 Compound: PL	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
HCT-116	EC₅₀	11.5 3 Compound: piperlongumine	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25826398]
HCT-116	IC₅₀	7.34 3 Compound: PL	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28434764]
CMK	IC₅₀	612.7 1 Compound: PL	Antiproliferative activity against human CMK cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human CMK cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
HCT-116	IC₅₀	7.34 3 Compound: PL	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28434764]
HCT-116	IC₅₀	8.13 3 Compound: 1	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29424539]
HCT-116	IC₅₀	8.13 3 Compound: 1	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29424539]
DU-145	GI₅₀	7.1 3 Compound: 1; PL	Growth inhibition of human DU145 cells after 48 hrs by WST-1 assay Growth inhibition of human DU145 cells after 48 hrs by WST-1 assay	[PMID: 29807795]
DU-145	IC₅₀	3.4 3 Compound: PL	Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition	[PMID: 33930801]
HCT-116	IC₅₀	8.13 3 Compound: Piperlongumine	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28686911]
HCT-116	IC₅₀	8.13 3 Compound: Piperlongumine	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28686911]
HCT-116	IC₅₀	8.17 3 Compound: 1	Antiproliferative activity against human HCT116 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
HCT-116	IC₅₀	8.17 3 Compound: 1	Antiproliferative activity against human HCT116 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
HCT-116	IC₅₀	13.9 3 Compound: PL	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 33930801]
HCT-116	EC₅₀	11.5 3 Compound: piperlongumine	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25826398]
HCT-116	IC₅₀	9.2 3 Compound: 1; PL	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
HCT-116	IC₅₀	13.3 3 Compound: 1	Antiproliferative activity against human HCT-116 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 24 hrs by MTT assay	[PMID: 39045852]
HCT-8	IC₅₀	4.1 3 Compound: 1	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 29424539]
HCT-116	IC₅₀	6.04 3 Compound: PL	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24937186]
HCT-8	IC₅₀	4.1 3 Compound: Piperlongumine	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 28686911]
HCT-116	IC₅₀	13.9 3 Compound: PL	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 33930801]
HCT-116	IC₅₀	9.2 3 Compound: 1; PL	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
HCT-116	IC₅₀	6.04 3 Compound: PL	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24937186]
HCT-116	IC₅₀	6.9 3 Compound: PL	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HeLa	IC₅₀	16.3 3 Compound: 8	Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay	[PMID: 34669417]
Hep 3B2	IC₅₀	69.46 3 Compound: PL	Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay	[PMID: 24937186]
HCT-116	IC₅₀	6.38 3 Compound: PL	Cytotoxicity against human HCT-116 incubated for 24 hrs by CCK-8 assay Cytotoxicity against human HCT-116 incubated for 24 hrs by CCK-8 assay	[PMID: 35696861]
HCT-116	IC₅₀	6.38 3 Compound: PL	Cytotoxicity against human HCT-116 incubated for 24 hrs by CCK-8 assay Cytotoxicity against human HCT-116 incubated for 24 hrs by CCK-8 assay	[PMID: 35696861]
HCT-116	IC₅₀	6.9 3 Compound: PL	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HCT-8	IC₅₀	4.1 3 Compound: 1	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 29424539]
HepG2	IC₅₀	6.8 3 Compound: 1	Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
HepG2	IC₅₀	6.8 3 Compound: PL	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HCT-8	IC₅₀	4.1 3 Compound: Piperlongumine	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 28686911]
HCT-116	IC₅₀	7.34 3 Compound: PL	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28434764]
HCT-116	IC₅₀	8.13 3 Compound: 1	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29424539]
HCT-8	IC₅₀	2.2 3 Compound: PL	Antiproliferative activity against human HCT-8 cells assessed as cell growth inhibition Antiproliferative activity against human HCT-8 cells assessed as cell growth inhibition	[PMID: 33930801]
HepG2	IC₅₀	8.9 3 Compound: 1; PL	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
HFF-1	EC₅₀	13.1 3 Compound: piperlongumine	Antiproliferative activity against HFF1 cells after 72 hrs by MTT assay Antiproliferative activity against HFF1 cells after 72 hrs by MTT assay	[PMID: 25826398]
HCT-116	IC₅₀	8.13 3 Compound: Piperlongumine	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28686911]
HeLa	IC₅₀	5.148 3 Compound: PL	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
HGC-27	IC₅₀	8.1 3 Compound: PL	Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HCT-116	IC₅₀	8.17 3 Compound: 1	Antiproliferative activity against human HCT116 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
HeLa	IC₅₀	16.3 3 Compound: 8	Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay	[PMID: 34669417]
HCT-116	IC₅₀	8.6 3 Compound: 1	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by MTT assay	[PMID: 39045852]
HGC-27	IC₅₀	8.2 3 Compound: 1	Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
Hep 3B2	IC₅₀	69.46 3 Compound: PL	Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay	[PMID: 24937186]
HL-60	IC₅₀	1128 1 Compound: PL	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
HCT-116	IC₅₀	9.2 3 Compound: 1; PL	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
HepG2	IC₅₀	8.623 3 Compound: PL	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
HL-60	IC₅₀	1778 1 Compound: PL	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
HepG2	IC₅₀	6.8 3 Compound: 1	Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
HL-60	IC₅₀	2250 1 Compound: PL	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
HCT-8	IC₅₀	2.2 3 Compound: PL	Antiproliferative activity against human HCT-8 cells assessed as cell growth inhibition Antiproliferative activity against human HCT-8 cells assessed as cell growth inhibition	[PMID: 33930801]
HepG2	IC₅₀	8.9 3 Compound: 1; PL	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
HL-60	IC₅₀	529.2 1 Compound: PL	Antiproliferative activity against human HL60 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
HepG2	IC₅₀	6.8 3 Compound: PL	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HCT-8	IC₅₀	4.1 3 Compound: 1	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 29424539]
HT-1080	IC₅₀	3.43 3 Compound: PL	Cytotoxicity against human HT1080 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human HT1080 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
HCT-8	IC₅₀	4.1 3 Compound: Piperlongumine	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 28686911]
HFF-1	EC₅₀	13.1 3 Compound: piperlongumine	Antiproliferative activity against HFF1 cells after 72 hrs by MTT assay Antiproliferative activity against HFF1 cells after 72 hrs by MTT assay	[PMID: 25826398]
HT-29	ED₅₀	0.45 6 Compound: 3	Cytotoxicity against human HT-29 cells after 6 days by MTT assay Cytotoxicity against human HT-29 cells after 6 days by MTT assay	[PMID: 2089124]
HFF-1	EC₅₀	13.1 3 Compound: piperlongumine	Antiproliferative activity against HFF1 cells after 72 hrs by MTT assay Antiproliferative activity against HFF1 cells after 72 hrs by MTT assay	[PMID: 25826398]
HGC-27	IC₅₀	0.76 3 Compound: PL	Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition	[PMID: 33930801]
HGC-27	IC₅₀	8.2 3 Compound: 1	Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
HT-29	IC₅₀	2.65 3 Compound: 1	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29424539]
HGC-27	IC₅₀	0.76 3 Compound: PL	Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition	[PMID: 33930801]
HT-29	IC₅₀	2.65 3 Compound: Piperlongumine	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 28686911]
HGC-27	IC₅₀	8.1 3 Compound: PL	Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HGC-27	IC₅₀	8.1 3 Compound: PL	Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
HT-29	IC₅₀	5.49 3 Compound: PL	Cytotoxicity against human HT-29 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human HT-29 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
HGC-27	IC₅₀	8.2 3 Compound: 1	Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
HL-60	IC₅₀	5.3 3 Compound: PL	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition	[PMID: 33930801]
Jurkat	IC₅₀	1.4 3 Compound: 1; PL	Antiproliferative activity in human Jurkat cells assessed as cell viability after 48 hrs by alamarBlue assay Antiproliferative activity in human Jurkat cells assessed as cell viability after 48 hrs by alamarBlue assay	[PMID: 27689728]
HL-60	IC₅₀	1128 1 Compound: PL	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
HT-1080	IC₅₀	3.43 3 Compound: PL	Cytotoxicity against human HT1080 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human HT1080 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
HL-60	IC₅₀	1778 1 Compound: PL	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
HT-29	ED₅₀	0.45 6 Compound: 3	Cytotoxicity against human HT-29 cells after 6 days by MTT assay Cytotoxicity against human HT-29 cells after 6 days by MTT assay	[PMID: 2089124]
Jurkat	IC₅₀	5 3 Compound: 1; PL	Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay	[PMID: 27689728]
HT-29	IC₅₀	2.65 3 Compound: 1	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29424539]
HL-60	IC₅₀	2250 1 Compound: PL	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
K562	IC₅₀	5.05 3 Compound: 1	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29424539]
HL-60	IC₅₀	5.3 3 Compound: PL	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition	[PMID: 33930801]
HT-29	IC₅₀	2.65 3 Compound: Piperlongumine	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 28686911]
K562	IC₅₀	5.09 3 Compound: 1	Antiproliferative activity against human K562 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human K562 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
HL-60	IC₅₀	529.2 1 Compound: PL	Antiproliferative activity against human HL60 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
HT-29	IC₅₀	1.4 3 Compound: PL	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition	[PMID: 33930801]
KB	IC₅₀	1.67 3 Compound: 1; PL	Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
KB	ED₅₀	1.8 6 Compound: 3	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 2089124]
HT-1080	IC₅₀	3.43 3 Compound: PL	Cytotoxicity against human HT1080 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human HT1080 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
HT-29	IC₅₀	5.49 3 Compound: PL	Cytotoxicity against human HT-29 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human HT-29 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
LNCaP	GI₅₀	> 10 3 Compound: 1; PL	Growth inhibition of human LNCAP cells after 24 to 48 hrs by WST-1 assay Growth inhibition of human LNCAP cells after 24 to 48 hrs by WST-1 assay	[PMID: 29807795]
HT-29	EC₅₀	0.54 3 Compound: Piperlongumine	Anti-necroptosis activity against TNFalpha-induced human HT-29 cells assessed as reduction in cell viability measured after 1 hr by Cell-titer glo luminescent based analysis Anti-necroptosis activity against TNFalpha-induced human HT-29 cells assessed as reduction in cell viability measured after 1 hr by Cell-titer glo luminescent based analysis	[PMID: 38199165]
Jurkat	IC₅₀	5.3 3 Compound: PL	Antiproliferative activity against human Jurkat cells assessed as cell growth inhibition Antiproliferative activity against human Jurkat cells assessed as cell growth inhibition	[PMID: 33930801]
LNCaP	GI₅₀	9.2 3 Compound: 1; PL	Growth inhibition of human LNCAP cells after 48 hrs by WST-1 assay Growth inhibition of human LNCAP cells after 48 hrs by WST-1 assay	[PMID: 29807795]
HT-29	ED₅₀	0.45 6 Compound: 3	Cytotoxicity against human HT-29 cells after 6 days by MTT assay Cytotoxicity against human HT-29 cells after 6 days by MTT assay	[PMID: 2089124]
Jurkat	IC₅₀	1.4 3 Compound: 1; PL	Antiproliferative activity in human Jurkat cells assessed as cell viability after 48 hrs by alamarBlue assay Antiproliferative activity in human Jurkat cells assessed as cell viability after 48 hrs by alamarBlue assay	[PMID: 27689728]
MCF-10A	EC₅₀	18.1 3 Compound: piperlongumine	Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 25826398]
HT-29	IC₅₀	1.4 3 Compound: PL	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition	[PMID: 33930801]
Jurkat	IC₅₀	5 3 Compound: 1; PL	Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay	[PMID: 27689728]
K562	IC₅₀	5.05 3 Compound: 1	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29424539]
HT-29	IC₅₀	2.65 3 Compound: 1	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29424539]
MCF7	IC₅₀	1.2 3 Compound: 1; PL	Antiproliferative activity in human MCF7 cells assessed as cell viability after 48 hrs by alamarBlue assay Antiproliferative activity in human MCF7 cells assessed as cell viability after 48 hrs by alamarBlue assay	[PMID: 27689728]
HT-29	IC₅₀	2.65 3 Compound: Piperlongumine	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 28686911]
K562	IC₅₀	5.09 3 Compound: 1	Antiproliferative activity against human K562 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human K562 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
MCF7	IC₅₀	4.4 3 Compound: 1; PL	Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
MCF7	IC₅₀	6.14 3 Compound: PL	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
HT-29	IC₅₀	5.49 3 Compound: PL	Cytotoxicity against human HT-29 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human HT-29 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
K562	IC₅₀	5.7 3 Compound: PL	Antiproliferative activity against human K562 cells assessed as cell growth inhibition Antiproliferative activity against human K562 cells assessed as cell growth inhibition	[PMID: 33930801]
MCF7	IC₅₀	8 3 Compound: 1; PL	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 27689728]
KB	ED₅₀	1.8 6 Compound: 3	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 2089124]
HaCaT	EC₅₀	4.46 3 Compound: piperlongumine	Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay Antiproliferative activity against human HaCaT cells after 72 hrs by MTT assay	[PMID: 25826398]
MDA-MB-231	IC₅₀	10.6 3 Compound: PL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28434764]
HaCaT	IC₅₀	16 3 Compound: PL, piplartine	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	[PMID: 25305718]
KB	IC₅₀	1.67 3 Compound: 1; PL	Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
HaCaT	IC₅₀	3.03 3 Compound: 3	Cytotoxicity against human HaCaT assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
MDA-MB-231	IC₅₀	3.72 3 Compound: 1; PL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
MDA-MB-231	IC₅₀	8.46 3 Compound: PL	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24937186]
LNCaP	GI₅₀	>10 3 Compound: 1; PL	Growth inhibition of human LNCAP cells after 24 to 48 hrs by WST-1 assay Growth inhibition of human LNCAP cells after 24 to 48 hrs by WST-1 assay	[PMID: 29807795]
HeLa	IC₅₀	16.3 3 Compound: 8	Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay	[PMID: 34669417]
MOLM-13	IC₅₀	1838 1 Compound: PL	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay	[PMID: 27505848]
HeLa	IC₅₀	5.148 3 Compound: PL	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
LNCaP	GI₅₀	9.2 3 Compound: 1; PL	Growth inhibition of human LNCAP cells after 48 hrs by WST-1 assay Growth inhibition of human LNCAP cells after 48 hrs by WST-1 assay	[PMID: 29807795]
MOLM-13	IC₅₀	934.5 1 Compound: PL	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
Hep 3B2	IC₅₀	69.46 3 Compound: PL	Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay	[PMID: 24937186]
MCF-10A	EC₅₀	18.1 3 Compound: piperlongumine	Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 25826398]
MRC5	IC₅₀	35.04 3 Compound: PL	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 24937186]
MCF7	IC₅₀	4.4 3 Compound: 1; PL	Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
HepG2	IC₅₀	6.8 3 Compound: 1	Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay	[PMID: 34806369]
MCF7	IC₅₀	25 3 Compound: PL	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 33930801]
HepG2	IC₅₀	6.8 3 Compound: PL	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33026807]
MRC5	IC₅₀	37 3 Compound: 1; PL	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 28159415]
MV4-11	IC₅₀	1439 1 Compound: PL	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 27505848]
HepG2	IC₅₀	8.623 3 Compound: PL	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
MCF7	IC₅₀	9.531 3 Compound: PL	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
MV4-11	IC₅₀	289.1 1 Compound: PL	Antiproliferative activity against human MV4-11 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
HepG2	IC₅₀	8.9 3 Compound: 1; PL	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28159415]
MCF7	IC₅₀	1.2 3 Compound: 1; PL	Antiproliferative activity in human MCF7 cells assessed as cell viability after 48 hrs by alamarBlue assay Antiproliferative activity in human MCF7 cells assessed as cell viability after 48 hrs by alamarBlue assay	[PMID: 27689728]
OCI-AML-3	IC₅₀	1109 1 Compound: PL	Antiproliferative activity against human OCI-AML3 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
Jurkat	IC₅₀	1.4 3 Compound: 1; PL	Antiproliferative activity in human Jurkat cells assessed as cell viability after 48 hrs by alamarBlue assay Antiproliferative activity in human Jurkat cells assessed as cell viability after 48 hrs by alamarBlue assay	[PMID: 27689728]
MCF7	IC₅₀	8 3 Compound: 1; PL	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 27689728]
OCI-AML-3	IC₅₀	1868 1 Compound: PL	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 27505848]
Jurkat	IC₅₀	5 3 Compound: 1; PL	Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay	[PMID: 27689728]
MCF7	IC₅₀	6.14 3 Compound: PL	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
P388	ED₅₀	0.9 6 Compound: 3	Cytotoxicity against mouse P388 cells after 3 days by MTT assay Cytotoxicity against mouse P388 cells after 3 days by MTT assay	[PMID: 2089124]
Jurkat	IC₅₀	5.3 3 Compound: PL	Antiproliferative activity against human Jurkat cells assessed as cell growth inhibition Antiproliferative activity against human Jurkat cells assessed as cell growth inhibition	[PMID: 33930801]
MDA-MB-231	IC₅₀	10.6 3 Compound: PL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28434764]
PANC-1	IC₅₀	3.2 3 Compound: PL, piplartine	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	[PMID: 25305718]
K562	IC₅₀	5.05 3 Compound: 1	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29424539]
MDA-MB-231	IC₅₀	3.72 3 Compound: 1; PL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
PC-3	GI₅₀	> 10 3 Compound: 1; PL	Growth inhibition of human PC3 cells after 24 to 48 hrs by WST-1 assay Growth inhibition of human PC3 cells after 24 to 48 hrs by WST-1 assay	[PMID: 29807795]
K562	IC₅₀	5.09 3 Compound: 1	Antiproliferative activity against human K562 cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human K562 cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
MDA-MB-231	IC₅₀	1.72 3 Compound: PL	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 33930801]
PC-3	GI₅₀	> 10 3 Compound: 1; PL	Growth inhibition of human PC3 cells after 48 hrs by WST-1 assay Growth inhibition of human PC3 cells after 48 hrs by WST-1 assay	[PMID: 29807795]
K562	IC₅₀	5.7 3 Compound: PL	Antiproliferative activity against human K562 cells assessed as cell growth inhibition Antiproliferative activity against human K562 cells assessed as cell growth inhibition	[PMID: 33930801]
MDA-MB-231	IC₅₀	8.46 3 Compound: PL	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24937186]
KB	ED₅₀	1.8 6 Compound: 3	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 2089124]
Platelet	IC₅₀	20.751 2 Compound: PL	Antiplatelet activity in rabbit plasma assessed as inhibition of arachidonic acid induced platelet aggregation by microplate reader analysis Antiplatelet activity in rabbit plasma assessed as inhibition of arachidonic acid induced platelet aggregation by microplate reader analysis	[PMID: 33930801]
Platelet	IC₅₀	6.71 2 Compound: PL	Antiplatelet activity in rabbit plasma assessed as inhibition of ADP induced platelet aggregation by microplate reader analysis Antiplatelet activity in rabbit plasma assessed as inhibition of ADP induced platelet aggregation by microplate reader analysis	[PMID: 33930801]
SAOS-2	IC₅₀	7.31 3 Compound: PL	Antiproliferative activity against human Saos2 cells after 72 hrs by MTT assay Antiproliferative activity against human Saos2 cells after 72 hrs by MTT assay	[PMID: 28434764]
KB	IC₅₀	1.67 3 Compound: 1; PL	Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
SF-188	IC₅₀	3.9 3 Compound: PL	Cytotoxicity against human SF188 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human SF188 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
LN-229	IC₅₀	10 3 Compound: PL	Antiproliferative activity against human LN-229 cells assessed as cell growth inhibition Antiproliferative activity against human LN-229 cells assessed as cell growth inhibition	[PMID: 33930801]
MRC5	IC₅₀	35.04 3 Compound: PL	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 24937186]
MRC5	IC₅₀	37 3 Compound: 1; PL	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 28159415]
LNCaP	GI₅₀	9.2 3 Compound: 1; PL	Growth inhibition of human LNCAP cells after 48 hrs by WST-1 assay Growth inhibition of human LNCAP cells after 48 hrs by WST-1 assay	[PMID: 29807795]
SH-SY5Y	IC₅₀	45.88 3 Compound: 3	Inhibition of TrxR in human SH-SY5Y cells using DTNB as substrate preincubated for 15 mins followed by substrate addition and measured for 20 mins by Ellman's method Inhibition of TrxR in human SH-SY5Y cells using DTNB as substrate preincubated for 15 mins followed by substrate addition and measured for 20 mins by Ellman's method	[PMID: 31400708]
SH-SY5Y	IC₅₀	5.94 3 Compound: 3	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
LNCaP	GI₅₀	> 10 3 Compound: 1; PL	Growth inhibition of human LNCAP cells after 24 to 48 hrs by WST-1 assay Growth inhibition of human LNCAP cells after 24 to 48 hrs by WST-1 assay	[PMID: 29807795]
MV4-11	IC₅₀	289.1 1 Compound: PL	Antiproliferative activity against human MV4-11 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
SK-BR-3	IC₅₀	4.04 3 Compound: PL	Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
MCF-10A	EC₅₀	18.1 3 Compound: piperlongumine	Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay Antiproliferative activity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 25826398]
SK-HEP1	IC₅₀	13.3 3 Compound: PL	Antiproliferative activity against human SKHEP1 cells after 72 hrs by MTT assay Antiproliferative activity against human SKHEP1 cells after 72 hrs by MTT assay	[PMID: 28434764]
P388	ED₅₀	0.9 6 Compound: 3	Cytotoxicity against mouse P388 cells after 3 days by MTT assay Cytotoxicity against mouse P388 cells after 3 days by MTT assay	[PMID: 2089124]
SK-MEL-2	EC₅₀	4.39 3 Compound: piperlongumine	Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTT assay Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTT assay	[PMID: 25826398]
P388	IC₅₀	2.8 3 Compound: PL	Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition	[PMID: 33930801]
SW-620	IC₅₀	4.62 3 Compound: 1	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 29424539]
PANC-1	IC₅₀	3.2 3 Compound: PL, piplartine	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	[PMID: 25305718]
T98G	IC₅₀	4.92 3 Compound: PL	Cytotoxicity against human T98G cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human T98G cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
CMK	IC₅₀	421.8 1 Compound: PL	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
U2OS	IC₅₀	9.49 3 Compound: PL	Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay	[PMID: 28434764]
PC-3	GI₅₀	>10 3 Compound: 1; PL	Growth inhibition of human PC3 cells after 24 to 48 hrs by WST-1 assay Growth inhibition of human PC3 cells after 24 to 48 hrs by WST-1 assay	[PMID: 29807795]
U-87MG ATCC	IC₅₀	16.15 3 Compound: 1	Antiproliferative activity against human U87MG cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
PC-3	IC₅₀	4.9 3 Compound: PL	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 33930801]
U-87MG ATCC	IC₅₀	17.34 3 Compound: 1	Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay	[PMID: 29424539]
HL-60	IC₅₀	529.2 1 Compound: PL	Antiproliferative activity against human HL60 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
U-87MG ATCC	IC₅₀	7.18 3 Compound: 3	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
Platelet	IC₅₀	6.71 2 Compound: PL	Antiplatelet activity in rabbit plasma assessed as inhibition of ADP induced platelet aggregation by microplate reader analysis Antiplatelet activity in rabbit plasma assessed as inhibition of ADP induced platelet aggregation by microplate reader analysis	[PMID: 33930801]
U-937	IC₅₀	2174 1 Compound: PL	Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay	[PMID: 27505848]
Platelet	IC₅₀	20.751 2 Compound: PL	Antiplatelet activity in rabbit plasma assessed as inhibition of arachidonic acid induced platelet aggregation by microplate reader analysis Antiplatelet activity in rabbit plasma assessed as inhibition of arachidonic acid induced platelet aggregation by microplate reader analysis	[PMID: 33930801]
CMK	IC₅₀	612.7 1 Compound: PL	Antiproliferative activity against human CMK cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human CMK cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
U-937	IC₅₀	767 1 Compound: PL	Antiproliferative activity against p53 null human U937 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
WI-38	IC₅₀	> 100 3 Compound: PL	Cytotoxicity against human W138 cells after 72 hrs by MTT assay Cytotoxicity against human W138 cells after 72 hrs by MTT assay	[PMID: 28434764]
WI-38	EC₅₀	20.3 3 Compound: PL	Senolytic activity against non-senescent human WI38 cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry Senolytic activity against non-senescent human WI38 cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry	[PMID: 29925484]
U-937	IC₅₀	767 1 Compound: PL	Antiproliferative activity against p53 null human U937 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
WI-38	IC₅₀	26.78 3 Compound: PL	Cytotoxicity against human WI38 cells after 72 hrs by MTT assay Cytotoxicity against human WI38 cells after 72 hrs by MTT assay	[PMID: 24937186]
SAOS-2	IC₅₀	7.31 3 Compound: PL	Antiproliferative activity against human Saos2 cells after 72 hrs by MTT assay Antiproliferative activity against human Saos2 cells after 72 hrs by MTT assay	[PMID: 28434764]
MCF7	IC₅₀	1.2 3 Compound: 1; PL	Antiproliferative activity in human MCF7 cells assessed as cell viability after 48 hrs by alamarBlue assay Antiproliferative activity in human MCF7 cells assessed as cell viability after 48 hrs by alamarBlue assay	[PMID: 27689728]
WI-38	EC₅₀	8 3 Compound: PL	Senolytic activity against ionizing radiation induced human WI38 senescent cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry Senolytic activity against ionizing radiation induced human WI38 senescent cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry	[PMID: 29925484]
SF-188	IC₅₀	3.9 3 Compound: PL	Cytotoxicity against human SF188 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human SF188 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
MOLM-13	IC₅₀	934.5 1 Compound: PL	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
MCF7	IC₅₀	25 3 Compound: PL	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 33930801]
ZR-75-30	IC₅₀	5.86 3 Compound: PL	Cytotoxicity against human ZR75-30 cells after 72 hrs by MTT assay Cytotoxicity against human ZR75-30 cells after 72 hrs by MTT assay	[PMID: 24937186]
MCF7	IC₅₀	4.4 3 Compound: 1; PL	Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
OCI-AML-3	IC₅₀	1109 1 Compound: PL	Antiproliferative activity against human OCI-AML3 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
MCF7	IC₅₀	6.14 3 Compound: PL	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
HL-60	IC₅₀	1128 1 Compound: PL	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
MCF7	IC₅₀	8 3 Compound: 1; PL	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 27689728]
MV4-11	IC₅₀	1439 1 Compound: PL	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 27505848]
MCF7	IC₅₀	9.531 3 Compound: PL	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
HL-60	IC₅₀	1778 1 Compound: PL	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
MOLM-13	IC₅₀	1838 1 Compound: PL	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay	[PMID: 27505848]
MDA-MB-231	IC₅₀	1.72 3 Compound: PL	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 33930801]
OCI-AML-3	IC₅₀	1868 1 Compound: PL	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 27505848]
MDA-MB-231	IC₅₀	10.6 3 Compound: PL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28434764]
SH-SY5Y	IC₅₀	5.94 3 Compound: 3	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
MDA-MB-231	IC₅₀	3.72 3 Compound: 1; PL	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 32736231]
CMK	IC₅₀	1911 1 Compound: PL	Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
MDA-MB-231	IC₅₀	8.46 3 Compound: PL	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24937186]
SH-SY5Y	IC₅₀	45.88 3 Compound: 3	Inhibition of TrxR in human SH-SY5Y cells using DTNB as substrate preincubated for 15 mins followed by substrate addition and measured for 20 mins by Ellman's method Inhibition of TrxR in human SH-SY5Y cells using DTNB as substrate preincubated for 15 mins followed by substrate addition and measured for 20 mins by Ellman's method	[PMID: 31400708]
MGC-803	IC₅₀	2.285 3 Compound: PL	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 36162214]
U-937	IC₅₀	2174 1 Compound: PL	Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay	[PMID: 27505848]
MKN-45	IC₅₀	20 3 Compound: PL	Antiproliferative activity against human MKN-45 cells assessed as cell growth inhibition Antiproliferative activity against human MKN-45 cells assessed as cell growth inhibition	[PMID: 33930801]
SK-BR-3	IC₅₀	4.04 3 Compound: PL	Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
HL-60	IC₅₀	2250 1 Compound: PL	Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against Ara-C resistant human HL60 cells after 72 hrs by MTT assay	[PMID: 27505848]
SK-HEP1	IC₅₀	13.3 3 Compound: PL	Antiproliferative activity against human SKHEP1 cells after 72 hrs by MTT assay Antiproliferative activity against human SKHEP1 cells after 72 hrs by MTT assay	[PMID: 28434764]
SK-MEL-2	EC₅₀	4.39 3 Compound: piperlongumine	Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTT assay Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTT assay	[PMID: 25826398]
MOLM-13	IC₅₀	1838 1 Compound: PL	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs by MTT assay	[PMID: 27505848]
CMK	IC₅₀	2815 1 Compound: PL	Antiproliferative activity against human CMK cells after 72 hrs by MTT assay Antiproliferative activity against human CMK cells after 72 hrs by MTT assay	[PMID: 27505848]
MOLM-13	IC₅₀	934.5 1 Compound: PL	Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human MOLM13 cells harboring wild type p53/FLT3-ITD mutant after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
SW-620	IC₅₀	4.62 3 Compound: 1	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 29424539]
MOLT-4	IC₅₀	1.7 3 Compound: PL	Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition	[PMID: 33930801]
T98G	IC₅₀	4.92 3 Compound: PL	Cytotoxicity against human T98G cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human T98G cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
MRC5	IC₅₀	35.04 3 Compound: PL	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 24937186]
U2OS	IC₅₀	9.49 3 Compound: PL	Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay	[PMID: 28434764]
MRC5	IC₅₀	37 3 Compound: 1; PL	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 28159415]
U-87MG ATCC	IC₅₀	10 3 Compound: PL	Antiproliferative activity against human U87 cells assessed as cell growth inhibition Antiproliferative activity against human U87 cells assessed as cell growth inhibition	[PMID: 33930801]
U-87MG ATCC	IC₅₀	17.34 3 Compound: 1	Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay	[PMID: 29424539]
MV4-11	IC₅₀	1439 1 Compound: PL	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 27505848]
U-87MG ATCC	IC₅₀	16.15 3 Compound: 1	Antiproliferative activity against human U87MG cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
MV4-11	IC₅₀	289.1 1 Compound: PL	Antiproliferative activity against human MV4-11 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
NSCLC	IC₅₀	9.2 3 Compound: PL	Cytotoxicity against human NSCLC cells assessed as cell growth inhibition Cytotoxicity against human NSCLC cells assessed as cell growth inhibition	[PMID: 33930801]
U-87MG ATCC	IC₅₀	7.18 3 Compound: 3	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
OCI-AML-3	IC₅₀	1109 1 Compound: PL	Antiproliferative activity against human OCI-AML3 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
U-937	IC₅₀	1.671 3 Compound: PL	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 36162214]
OCI-AML-3	IC₅₀	1868 1 Compound: PL	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay Antiproliferative activity against human OCI-AML3 cells after 72 hrs by MTT assay	[PMID: 27505848]
WI-38	EC₅₀	8 3 Compound: PL	Senolytic activity against ionizing radiation induced human WI38 senescent cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry Senolytic activity against ionizing radiation induced human WI38 senescent cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry	[PMID: 29925484]
P388	ED₅₀	0.9 6 Compound: 3	Cytotoxicity against mouse P388 cells after 3 days by MTT assay Cytotoxicity against mouse P388 cells after 3 days by MTT assay	[PMID: 2089124]
WI-38	EC₅₀	20.3 3 Compound: PL	Senolytic activity against non-senescent human WI38 cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry Senolytic activity against non-senescent human WI38 cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry	[PMID: 29925484]
P388	IC₅₀	2.8 3 Compound: PL	Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition	[PMID: 33930801]
WI-38	IC₅₀	>100 3 Compound: PL	Cytotoxicity against human W138 cells after 72 hrs by MTT assay Cytotoxicity against human W138 cells after 72 hrs by MTT assay	[PMID: 28434764]
PANC-1	IC₅₀	3.2 3 Compound: PL, piplartine	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	[PMID: 25305718]
WI-38	IC₅₀	26.78 3 Compound: PL	Cytotoxicity against human WI38 cells after 72 hrs by MTT assay Cytotoxicity against human WI38 cells after 72 hrs by MTT assay	[PMID: 24937186]
PC-3	GI₅₀	> 10 3 Compound: 1; PL	Growth inhibition of human PC3 cells after 24 to 48 hrs by WST-1 assay Growth inhibition of human PC3 cells after 24 to 48 hrs by WST-1 assay	[PMID: 29807795]
WI-38	IC₅₀	8 3 Compound: 1	Induction of senescence in human WI-38 cells Induction of senescence in human WI-38 cells	[PMID: 38436272]
PC-3	GI₅₀	> 10 3 Compound: 1; PL	Growth inhibition of human PC3 cells after 48 hrs by WST-1 assay Growth inhibition of human PC3 cells after 48 hrs by WST-1 assay	[PMID: 29807795]
WI-38	IC₅₀	8 3 Compound: PL	Senolytic activity in ionizing radiation induced human WI-38 senescent cells by PI staining based flow cytometry analysis Senolytic activity in ionizing radiation induced human WI-38 senescent cells by PI staining based flow cytometry analysis	[PMID: 38104906]
PC-3	IC₅₀	4.9 3 Compound: PL	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 33930801]
WI-38	IC₅₀	20.3 3 Compound: PL	Senolytic activity in non-senescent human WI-38 cells by PI staining based flow cytometry analysis Senolytic activity in non-senescent human WI-38 cells by PI staining based flow cytometry analysis	[PMID: 38104906]
ZR-75-30	IC₅₀	5.86 3 Compound: PL	Cytotoxicity against human ZR75-30 cells after 72 hrs by MTT assay Cytotoxicity against human ZR75-30 cells after 72 hrs by MTT assay	[PMID: 24937186]
Platelet	IC₅₀	20.751 2 Compound: PL	Antiplatelet activity in rabbit plasma assessed as inhibition of arachidonic acid induced platelet aggregation by microplate reader analysis Antiplatelet activity in rabbit plasma assessed as inhibition of arachidonic acid induced platelet aggregation by microplate reader analysis	[PMID: 33930801]
Platelet	IC₅₀	6.71 2 Compound: PL	Antiplatelet activity in rabbit plasma assessed as inhibition of ADP induced platelet aggregation by microplate reader analysis Antiplatelet activity in rabbit plasma assessed as inhibition of ADP induced platelet aggregation by microplate reader analysis	[PMID: 33930801]
RAW264.7	IC₅₀	3 3 Compound: 1	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production	[PMID: 25453809]
SAOS-2	IC₅₀	7.31 3 Compound: PL	Antiproliferative activity against human Saos2 cells after 72 hrs by MTT assay Antiproliferative activity against human Saos2 cells after 72 hrs by MTT assay	[PMID: 28434764]
SF-188	IC₅₀	3.9 3 Compound: PL	Cytotoxicity against human SF188 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human SF188 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
SH-SY5Y	IC₅₀	45.88 3 Compound: 3	Inhibition of TrxR in human SH-SY5Y cells using DTNB as substrate preincubated for 15 mins followed by substrate addition and measured for 20 mins by Ellman's method Inhibition of TrxR in human SH-SY5Y cells using DTNB as substrate preincubated for 15 mins followed by substrate addition and measured for 20 mins by Ellman's method	[PMID: 31400708]
SH-SY5Y	IC₅₀	5.94 3 Compound: 3	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
SK-BR-3	IC₅₀	4.04 3 Compound: PL	Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
SK-HEP1	IC₅₀	13.3 3 Compound: PL	Antiproliferative activity against human SKHEP1 cells after 72 hrs by MTT assay Antiproliferative activity against human SKHEP1 cells after 72 hrs by MTT assay	[PMID: 28434764]
SK-MEL-2	EC₅₀	4.39 3 Compound: piperlongumine	Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTT assay Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTT assay	[PMID: 25826398]
SW-620	IC₅₀	4.62 3 Compound: 1	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 29424539]
T98G	IC₅₀	4.92 3 Compound: PL	Cytotoxicity against human T98G cells assessed as cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human T98G cells assessed as cell viability after 72 hrs by resazurin reduction assay	[PMID: 26599530]
U-87MG ATCC	IC₅₀	10 3 Compound: PL	Antiproliferative activity against human U87 cells assessed as cell growth inhibition Antiproliferative activity against human U87 cells assessed as cell growth inhibition	[PMID: 33930801]
U-87MG ATCC	IC₅₀	16.15 3 Compound: 1	Antiproliferative activity against human U87MG cells after 72 hrs in presence of ligustrazine by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs in presence of ligustrazine by MTT assay	[PMID: 29424539]
U-87MG ATCC	IC₅₀	17.34 3 Compound: 1	Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay	[PMID: 29424539]
U-87MG ATCC	IC₅₀	7.18 3 Compound: 3	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31400708]
U-937	IC₅₀	1.671 3 Compound: PL	Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human U-937 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 36162214]
U-937	IC₅₀	2174 1 Compound: PL	Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs by MTT assay	[PMID: 27505848]
U-937	IC₅₀	767 1 Compound: PL	Antiproliferative activity against p53 null human U937 cells after 72 hrs in presence of SAHA by MTT assay Antiproliferative activity against p53 null human U937 cells after 72 hrs in presence of SAHA by MTT assay	[PMID: 27505848]
U2OS	IC₅₀	9.49 3 Compound: PL	Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay	[PMID: 28434764]
WI-38	EC₅₀	20.3 3 Compound: PL	Senolytic activity against non-senescent human WI38 cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry Senolytic activity against non-senescent human WI38 cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry	[PMID: 29925484]
WI-38	EC₅₀	8 3 Compound: PL	Senolytic activity against ionizing radiation induced human WI38 senescent cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry Senolytic activity against ionizing radiation induced human WI38 senescent cells assessed as reduction in cell viability by propidium iodide staining based flow cytometry	[PMID: 29925484]
WI-38	IC₅₀	20.3 3 Compound: PL	Senolytic activity in non-senescent human WI-38 cells by PI staining based flow cytometry analysis Senolytic activity in non-senescent human WI-38 cells by PI staining based flow cytometry analysis	[PMID: 38104906]
WI-38	IC₅₀	26.78 3 Compound: PL	Cytotoxicity against human WI38 cells after 72 hrs by MTT assay Cytotoxicity against human WI38 cells after 72 hrs by MTT assay	[PMID: 24937186]
WI-38	IC₅₀	8 3 Compound: 1	Induction of senescence in human WI-38 cells Induction of senescence in human WI-38 cells	[PMID: 38436272]
WI-38	IC₅₀	8 3 Compound: PL	Senolytic activity in ionizing radiation induced human WI-38 senescent cells by PI staining based flow cytometry analysis Senolytic activity in ionizing radiation induced human WI-38 senescent cells by PI staining based flow cytometry analysis	[PMID: 38104906]
WI-38	IC₅₀	> 100 3 Compound: PL	Cytotoxicity against human W138 cells after 72 hrs by MTT assay Cytotoxicity against human W138 cells after 72 hrs by MTT assay	[PMID: 28434764]
ZR-75-30	IC₅₀	5.86 3 Compound: PL	Cytotoxicity against human ZR75-30 cells after 72 hrs by MTT assay Cytotoxicity against human ZR75-30 cells after 72 hrs by MTT assay	[PMID: 24937186]

体外実験

Piplartine (5, 10, and 15 μM) significantly decreases cell proliferation of 786-O, SKBR3, Panc1, A549, and L3.6pL cancer cells after treatment for 24 and 48 hours, induces apoptosis and ROS in these cell lines at 5 and 10 μM after 3 or 9 h of treatment^[1].
Piplartine (5 or 10 μM) induces cleaved PARP and downregulates Sp1, Sp3, Sp4, and Sp-regulated genes^[1].
Piplartine (20 μM) decreases the viability of cardiac fibroblasts (CFs). Piplartine (0-10 μM) suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Piperlongumine (30 mg/kg/day, i.p. for 3 weeks) exhibits potent anti-tumor effect in athymic nude mice bearing L3.6pL cells without body weight loss^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

317.34

分子式

C₁₇H₁₉NO₅

CAS 番号

20069-09-4

Appearance

Solid

Color

White to yellow

SMILES

O=C1C=CCCN1C(/C=C/C2=CC(OC)=C(OC)C(OC)=C2)=O

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (315.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1512 mL	15.7560 mL	31.5119 mL
5 mM	0.6302 mL	3.1512 mL	6.3024 mL
10 mM	0.3151 mL	1.5756 mL	3.1512 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.86%

Select Batch:

データシート (276 KB) SDS (393 KB)

COA (249 KB) HNMR (259 KB) LCMS (95 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Karki K, et al. Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent Downregulation of Specificity Protein Transcription Factors. [Content Brief]

[2]. Wu X, e,t al. Piperlongumine inhibits angiotensin II-induced extracellular matrix expression in cardiac fibroblasts. J Cell Biochem. 2018 Dec;119(12):10358-10364 [Content Brief]

[3]. Yan Qin , et al. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation. Front Immunol. 2022 Nov 3;13:994828. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1512 mL	15.7560 mL	31.5119 mL	78.7799 mL
	5 mM	0.6302 mL	3.1512 mL	6.3024 mL	15.7560 mL
	10 mM	0.3151 mL	1.5756 mL	3.1512 mL	7.8780 mL
	15 mM	0.2101 mL	1.0504 mL	2.1008 mL	5.2520 mL
	20 mM	0.1576 mL	0.7878 mL	1.5756 mL	3.9390 mL
	25 mM	0.1260 mL	0.6302 mL	1.2605 mL	3.1512 mL
	30 mM	0.1050 mL	0.5252 mL	1.0504 mL	2.6260 mL
	40 mM	0.0788 mL	0.3939 mL	0.7878 mL	1.9695 mL
	50 mM	0.0630 mL	0.3151 mL	0.6302 mL	1.5756 mL
	60 mM	0.0525 mL	0.2626 mL	0.5252 mL	1.3130 mL
	80 mM	0.0394 mL	0.1969 mL	0.3939 mL	0.9847 mL
	100 mM	0.0315 mL	0.1576 mL	0.3151 mL	0.7878 mL

Piperlongumine Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Piperlongumine20069-09-4PiplartineERKReactive Oxygen Species (ROS)AutophagyApoptosisBacterialFerroptosisExtracellular signal regulated kinasesInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Piperlongumine (Synonyms: Piplartine; ピペルロングミン)

カスタマーレビュー

Other Forms of Piperlongumine:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

ERK アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Piperlongumine Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Piperlongumine (Synonyms: Piplartine; ピペルロングミン)

カスタマーレビュー

Other Forms of Piperlongumine:

Piperlongumine 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

ERK アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Piperlongumine 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Piperlongumine Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report